ArticleNature2026
Tumour-reactive heterotypic CD8 T cell clusters from clinical samples.
Abstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- T-cell activity feedback-guided photothermal immunotherapy enabled by immune-responsive redox nanodots.Materials today. Bio · 2026Article
- Temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggest a window of opportunity for checkpoint inhibitor therapy in prostate cancer.Journal for immunotherapy of cancer · 2026Article
- Epigenetic plus cytokine therapy induces stem-like CD8Journal for immunotherapy of cancer · 2026Article
- Decoding T cell exhaustion in the tumour microenvironment.Experimental & molecular medicine · 2026Review
- Living Inorganic Nanomaterials: Design, Preparation, and Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Decoding Immune Cell Doublets in Humans: From Artifacts to Insights.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2026Review
- Modeling TCR-Epitope Recognition Specificity: What We Should Learn to Succeed.Immunological reviews · 2026Review
- Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results.Cancer discovery · 2026Article
- PD-1 and TIGIT coexpression enables selective enrichment of clonally expanded tumor-reactive CD8 T cells for melanoma TIL therapy.Journal of translational medicine · 2026Article
- High-avidity TCR signaling induces a distinct KLR-positive exhaustion state in human tumor-infiltrating CD8 T cells associated with immunotherapy response.bioRxiv : the preprint server for biology · 2026Article
- Review
- Turep: Detecting cross-cancer tumor-reactive T cells in single-cell and spatial transcriptomics data.bioRxiv : the preprint server for biology · 2026Article
- Autologous tumor-immune effusion cocultures enable ex vivo functional profiling of radiotherapy-immunotherapy combinations.Journal of experimental & clinical cancer research : CR · 2026Article
- Beyond density: mapping the functional landscapes of macrophage-T lymphocyte niches in the tumor microenvironment.Frontiers in immunology · 2026Review
- Cluster-derived, tumour-reactive T cells from clinical samples.Nature reviews. Immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Sofía Ibáñez-Molero *Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Johanna Veldman *Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Juan Simon NietoDivision of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Joleen J H TraetsDivision of Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Austin GeorgeDivision of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0009-0006-4786-2988
Kelly HoefakkerDivision of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Anita KaromiDivision of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Rolf HarkesBioImaging Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0001-6592-654X
Bram van den BroekBioImaging Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0003-1037-907X
Su Min PackDivision of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0002-8480-238X
Liselotte TasDivision of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Nils L VisserDivision of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Susan E van Hal-van VeenDivision of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Paula Alóndiga-MéridaDivision of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Maartje AlkemadeCore Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Iris M SeignetteDepartment of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0009-0007-7757-698X
Renaud TissierBiostatistics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Marja NieuwlandGenomic Core Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Martijn van BaalenFlow Cytometry Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Joanna PoźniakLaboratory for Molecular Cancer Biology, Department of Oncology, VIB Center for Cancer Biology, KU Leuven, Leuven, Belgium.
Erik MulFlow Cytometry Facility, Sanquin, Amsterdam, The Netherlands.
Simon TolFlow Cytometry Facility, Sanquin, Amsterdam, The Netherlands.
Sofia StenqvistSahlgrenska Center for Cancer Research, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Lisa M NilssonSahlgrenska Center for Cancer Research, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Jonas A NilssonSahlgrenska Center for Cancer Research, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0003-0346-6837
John B A G HaanenDivision of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0001-5884-7704
Winan J van HoudtDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Daniel S PeeperDivision of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands. d.peeper@nki.nl.ORCID 0000-0003-1293-3177
Funding
Dutch Research CouncilOncode Institute, the Dutch Cancer Society KWF and by an ERC Advanced grant
Abstract
Emerging evidence suggests a correlation between CD8
Indexed as
CD8-Positive T-LymphocytesMelanomaAdoptive TransferAnimalsAntigen-Presenting CellsClone CellsFemaleFlow CytometryHumansLymphocyte ActivationMaleMiceReceptors, Antigen, T-CellSingle-Cell AnalysisReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.